PDF(Pubmed)
Abstract：
Rhabdomyolysis is a rare adverse reaction that has a previously established association with levetiracetam use, which selectively binds the synaptic vesicle glycoprotein 2A (SV2A). Its structural analogue, brivaracetam, is a new third-generation antiseizure medication that has a higher affinity for SV2A, and current data suggests it provides a more favorable adverse event profile. Here, however, we report a case of rhabdomyolysis requiring dialysis in which serum creatine kinase level increased rapidly for several days until brivaracetam was discontinued. The delayed creatine kinase peak, rapid decline upon discontinuation of brivaracetam, and prior association of rhabdomyolysis with levetiracetam strongly suggest a causal relationship. To date, there are three reported cases of brivaracetam-associated rhabdomyolysis in the food and drugs administration adverse event reporting system (FAERS). Despite its favorable side effects profile, the use of brivaracetam may be associated with life-threatening rhabdomyolysis.
摘要：
横纹肌溶解症是一种罕见的不良反应，以前与左乙拉西坦的使用有关联，选择性结合突触小泡糖蛋白2A（SV2A）。它的结构类似物，布立西坦,是一种新的第三代抗癫痫药物，对SV2A有更高的亲和力，和目前的数据表明，它提供了一个更有利的不良事件概况。这里,然而,我们报道了一例横纹肌溶解症需要透析的病例，其中血清肌酸激酶水平在数天内迅速升高，直至停用布立西坦。延迟的肌酸激酶峰值，停止服用布立拉西坦后迅速下降，横纹肌溶解症与左乙拉西坦的先前关联强烈表明存在因果关系。迄今为止,在食品和药物管理不良事件报告系统(FAERS)中,有3例报告了布立西坦相关横纹肌溶解症.尽管它有良好的副作用，布立西坦的使用可能与危及生命的横纹肌溶解有关.
